+44 (0)7508 050451 info@originbiomarkers.co.uk

About Origin Biomarkers

Origin Biomarkers Ltd was founded in 2008 in England, UK and moved to Scotland in 2013.

About Origin Biomarkers

The company has developed several novel medical diagnostic blood tests for the detection of pregnancy disorders at the first trimester, and for the prediction of success in fertility treatment (IVF). The work was supported by R&D grants in England (APOC & AWM) and Scotland (Scottish Enterprise SMART award).

EPO and USA patents are granted for the use of these biomarkers and the company now seeks licensing partners for the commercialisation of its technologies.

Origin Biomarkers also offers an in-house service for the analysis of pre-treatment IVF patients’ blood serum as an aid to tailoring treatment plans and improving IVF pregnancy rates. Depending on the number of samples required to be tested, the price for this in-house service is negotiable.

Established October 2008

History in innovating in medical diagnostic tests

Advanced medical diagnostic tests

Unique biomarker testing for early detection for pregnancy related conditions

Intellectual Property

Patents granted (USA & EPO) for diagnostic and therapeutic applications of soluble LHCGR protein.

Our Publications on LH/hCG receptor

Banerjee S, Smallwood A, Chambers AE, Papageorghiou A, Loosfelt H, Spencer K, Campbell S, Nicolaides K: A link between high serum levels of human chorionic gonadotrophin and chorionic expression of its mature functional receptor (LHCGR) in Down's syndrome pregnancies. Reprod Biol Endocrinol2005, 3:25
Abstract | HTML | PDF

Chambers AE, Stanley PF, Randeva H, Banerjee S. Microvesicle-mediated release of soluble LH/hCG receptor (LHCGR) from transfected cells and placenta explants. Reprod Biol Endocrinol. 2011 May 15;9:64. doi: 10.1186/1477-7827-9-64.
Abstract | HTML | PDF

Chambers AE, Nayini KP, Mills WE, Lockwood GM, Banerjee S. Circulating LH/hCG receptor (LHCGR) may identify pre-treatment IVF patients at risk of OHSS and poor implantation. Reprod Biol Endocrinol. 2011 Dec 23;9:161. doi: 10.1186/1477-7827-9-161.
Abstract | HTML | PDF

Chambers AE, Griffin C, Naif SA, Mills I, Mills WE, Syngelaki A, Nicolaides KH, Banerjee S. Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, Down's syndrome, preterm delivery and preeclampsia. Reprod Biol Endocrinol. 2012 Dec 17;10:113. doi: 10.1186/1477-7827-10-113.
Abstract | HTML | PDF

Chambers AE, Mills WE, Mercadé I, Crovetto F, Crispi F, Bodi LR, Pugia M, Mira A, Lasalvia L, Banerjee S, Casals E, Gratacos E. The utility of circulating LHCGR as a predictor of Down's syndrome in early pregnancy. BMC Pregnancy Childbirth. 2014 Jun 6;14:197. doi: 10.1186/1471-2393-14-197.
Abstract | HTML | PDF

Crovetto F, Figueras F, Crispi F, Triunfo S, Pugia M, Lasalvia L, Chambers AE, Mills WE, Banerjee S, Mercadé I, Casals E, Mira A, Rodriguez-Revenga Bodi L, Gratacós E.
Forms of Circulating Luteinizing Hormone Human Chorionic Gonadotropin Receptor for the Prediction of Early and Late Preeclampsia in the First Trimester of Pregnancy.
Fetal Diagn Ther. 2015 Feb 11. [Epub ahead of print]